Speaker

Mr Johnson Chui joined HKEX as Managing Director and Head of Global Issuer Services in September 2024.

In his role, Mr Chui leads HKEX’s Global Issuer Services teams based in Hong Kong, Mainland China, London and Singapore, driving the Group’s efforts to further diversify and expand its listed issuer base.

Mr Chui has more than 25 years of experience working in international capital markets. Prior to joining HKEX, he held senior positions at Nomura, where he was Managing Director, Vice Chairman of Investment Banking and Head of Equity Capital Markets, Asia ex-Japan.

Prior to Nomura, Mr Chui spent nearly 18 years at Credit Suisse, where he was Head of Equity Capital Markets for Asia-Pacific and a member of the Operating Committees for Global Equity Capital Markets and Asia Pacific Investment Banking & Capital Markets. He has also held senior investment banking roles at Citigroup and Goldman Sachs in Hong Kong.

Mr Chui holds Bachelor of Laws and Bachelor of Commerce (Finance) degrees from the University of New South Wales in Australia.

Mr Lot Chan studied pharmacy in UK and public health in Hong Kong. He has joined the Department of Health of the Government of Hong Kong Special Administrative Region for 30 years. For may years he has been involved in the approval of pharmaceutical products registration and clinical trials, import/export control of medicines, licensing and inspection of pharmaceutical traders, and enforcement of drug-related laws. During his service in the Department of Health, Mr Lot Chan has led the application for the accession to the Pharmaceutical Inspection Co-operation Scheme and the statutory regulation of advanced therapy products.

Currently, Mr Lot Chan is the Assistant Director of Health, responsible for the preparatory work of the establishment of the Centre for Medical Products Regulation (CMPR).

Ma Jie is the head of the National Center for Clinical Laboratories and the Biotherapy Center at Beijing Hospital, and a doctoral supervisor.

Professor Ma is one of the Beijing 100 Leading Talents in Science and Technology, one of the national candidates for the New Century Millions of Talents Project, a State Council Special Allowance expert, the chief expert of a state – key research and development project, the chief expert of a national science and technology major project, and an expert for the “12th Five-Year Major New Drug Creation” and “14th Five-Year Special Guidelines for Stem Cell and Tissue Repair”.

The tumor cell immunotherapy program developed by Professor Ma received two phase II clinical trial approvals from the State Food and Drug Administration in 2022. Currently, Professor Ma has carried out a number of phase I clinical research projects of tumor immunotherapy, and has won the First Prize of the Beijing Medical Science and Technology Award, the Third Prize of the Beijing Science and Technology Award, and the Second Prize of the China Medical Science and Technology Award, making important contributions to the promotion of tumor immunotherapy in China.

Professor Ma’s research interests include target screening and new technology development for tumor immunotherapy; Research and development of anti-tumor nanomedicine and new dosage forms modified by nanotechnology; Clinical application of tumor targeting therapy and immunotherapy, etc.

Mark Tang is the Managing Director of Good Health Capital, a healthcare PEVC firm with offices in New York and Shanghai, and Chairperson of World Biotech Capital LLC, a cross-border venture capital, M&A, licensing, and IPO advisory firm. Mark is also a co-founder of 111 Longevity LLC and Phagionics Inc. Originally from mainland China and educated in the US, Mark is a veteran Chinese biotech investor with over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He served as the biotech director at Rutgers Business School and as a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of “The Essential Biotech Investment Handbook,” which is published in both English and Chinese. Mark has co-founded three tech startups that have achieved successful exits. He holds degrees from NYU Stern School of Business and the Harvard T.H. Chan School of Public Health.

Xian-En Zhang is a Chair Professor of the Faculty of Synthetic Biology, Shenzhen University of Advanced Technology and retired PI Professor of the Inst. Biophys, Chinese Acad. Sci. (CAS). He received MPhil. And Ph.D. from the CAS institutes, and Honorary Doctor of Science Degree from the University of Alberta, Canada. He became a full professor in 1993 at the Wuhan Inst. Virol., CAS. 

He has been engaged in interdisciplinary research at the intersection of biosensing, nanobiology, and synthetic biology, applying these approaches to address scientific questions in virology and cancer biology.

His is an elected Fellow of American Institute of Medicine and Biological Engineering and a Fellow of Royal Society Chemistry. He serves as the coordinator of the expert group of the China synthetic biology research program. He also serves as the Vice President of Chinese Society of Biotechnology, member of the organizing committee of the World Congress on Biosensors, and founding co-chair of the Division of Nanobiotechnology/Biosensors/Biochips, Asian Federation of Biotechnology.

Dr. Qiang Cheng obtained his Ph.D. from Peking University in 2016 and subsequently completed his postdoctoral training at the University of Texas Southwestern Medical Center (UTSW) during 2017 to 2021. Since September 2021, Dr. Cheng established his research lab as an Assistant Professor at Peking University. His research interests focus on mRNA targeted delivery. The core is to innovate lipid nanoparticle (LNP) delivery technology to achieve targeted delivery of mRNA in tissues and cells, providing a powerful tool for precise mRNA-based therapy to address unmet clinical needs. To date Dr. Cheng has developed tissue-targeted (SORT, PILOT, STAR) and cell-targeted (SELECT) mRNA-LNP delivery platforms, enabling targeted delivery and treatment of mRNA drugs in various major organs and cells, including the liver, lungs, spleen, bone, muscle, thymus, kidneys, and tumors. These works have been published as first or corresponding author in journals including Nature Materials (2025, 2021), Nature Nanotechnology (2020), Nature Communications (2023, 2020), PNAS (2023, 2021), and Advanced Materials (2024, 2023, 2018). Notably, the Selective Organ Targeting (SORT) mRNA-LNP technology was highlighted in “Seven Technologies to Watch in 2022” by Nature. Several international patents resulting from his research have been commercialized, leading to the advancement of at least two pipeline projects into Phase 1 clinical trials and the initiation of multiple new mRNA drugs into Investigator Initiated Trial (IIT).

Dr. Destura is a molecular microbiologist and infectious disease specialist. He took his bachelor’s degree in Microbiology at the University of Sto. Tomas holds a medical degree and specialty in internal medicine at the De la Salle Health Sciences Institute. He went to the University of the Philippines for his subspecialty training in Infectious Diseases.

He received a research scholarship to the International Training and Fellowship on Emerging Infectious Diseases at the Center for Global Health, University of Virginia School of Medicine. He also holds a master’s degree in Business Administration from Ateneo Graduate School of Business.
He is a diplomate and fellow in Infectious Diseases. He joined the NIH Philippines and became director of the National Institute of Molecular Biology and Biotechnology.
He dedicated his work to the identification of diagnostic targets and the evaluation of diagnostic platforms best suited in a developing country scenario. His most important work is the “Lab-in-a-mug” project which functions as a multi-infectious disease diagnostic platform with its principal product the Biotek-MTM Dengue aqua kit that received local and international recognition such as the NSTW Outstanding Technology Commercialization Award given by the National Academy of Science and Technology (2016), as a gold medalist in the 46th International Invention Exhibition in Geneva, Switzerland, in 2018, Gawad Dagisik for Medical Sciences was given by the Department of Science and Technology in 2019.
Through the Technology Transfer Act of 2009, he built Manila HealthTek Incorporated, the very first university spin-off company from the University of the Philippines in Health Biotechnology. He is a recipient of national and international awards, including the Bill and Melinda Gates travel scholarship in Molecular Helminthology in 2005, Outstanding Young Scientist of the Philippines for Medicine in 2008; UP Manila Research Productivity award, the Top 20 Young Physician Leaders from the Inter-academy Medical Panel in Berlin, Germany, and The Outstanding Young Men (TOYM) all given in 2011; Dr. Jose P. Rizal National Award in Research from the Philippine Medical Association and Dr. Eusebio Y. Garcia Award in Molecular Biology and Molecular Pathology from the National Research Council of the Philippines in 2015. In 2019, he received the Presidential Lingkod Bayan Award from the President of the Philippines. In 2020, he was named among top 100 Asian Scientist in the Asian Science Magazine. His latest work is the local RT-PCR kit for the detection of the SARS-CoV-2 virus. In 2024 he received the Alberto G. Romualdez, Jr. Outstanding Health Research Award (Biomedical Research Category) from the Department of Health – PCHRD for his research on the “Molecular Diagnosis of Infectious Diseases Program.”

Dr. Zheng focuses on advancing biotechnology to solve clinical problems. Dr. Zheng invented the AMP technology that has been adopted globally for robust molecular diagnosis in both research and clinical settings to guide targeted therapies for cancer patients. Dr. Zheng’s pioneering work in precision genome editing includes the CRISPR off-target analysis method GUIDE-seq that is widely used and supported the first FDA-approved therapy utilizing CRISPR Cas9. Dr. Zheng is dedicated to ‘liquid biopsy’ and ‘DNA surgery’ research and clinical applications.

Professor Chak-sing Lau is currently Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong. He is meanwhile Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the University’s Li Ka Shing Faculty of Medicine (HKUMed).

He presided over the Hong Kong Academy of Medicine (2016 – 2020), a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. Today, he sits on numerous strategic committees/ working groups of the Health Bureau, Hospital Authority and Department of Health. He is also a member of the Research Council under the Health Bureau.

Professor Lau is known as a pioneer for establishing and advancing rheumatology in Hong Kong, Asia and beyond. In 2022, he was selected as an Honorary Member of the European Alliance of Associations for Rheumatology (EULAR), and elected as a Member of Academia Europaea in 2023, and conferred the degree of Doctor of Science honoris causa by the University of Glasgow in 2024. He is Honorary Fellow of the American College of Physicians; the Academy of Medicine, Singapore; the Singapore College of Physicians; the Royal College of Physicians of Thailand; the Academy of Medicine of Malaysia; the Royal College of Physicians of Ireland; and the Hong Kong Academy of Medicine. 

Director of GHM Institute of CNS Regeneration at Jinan University, Guangzhou, China; Emeritus Professor, The University of Hong Kong. Editor-in-Chief of Neural Regeneration Research. Received PhD degree from MIT. He is one of the pioneers in the field of axonal regeneration in the visual system. In 1995, obtained the Natural Science Award of the National Natural Science Foundation of China. 1999, was elected a Member of the Chinese Academy of Sciences. 2015 was elected FNAI, US National Academy of Inventors, Fellow.  In 2017, elected a member of DABI (Dana Alliance for Brain Initiatives, www.dana.org ), 2019 was elected Fellow of the Chinese Academy of Medical Science, and in 2021, elected member of the College of Fellows, American Institute for Medical and Biological Engineering (AIMBE FELLOW). 2021 – 2023  is listed as one of the world’s top 2% neuroscientists. “The World’s Top Neuroscientists (2023)” – Top Ten in China, Cited more than 28,075 times, H-index 88 (GOOGLE SCHOLAR). He is the author and co-author of over 500+ published SCI papers; co-inventor of 46 patents.